National survey of feasibility of NIV trials for management of children with bronchiolitis. by Rosala-Hallas, A et al.
 
Rosala-Hallas, A, Jones, AP, Bedson, E, Compton, V, Fernandes, RM, Lacy, D, 
Lyttle, MD, Peak, M, Thorburn, K, van Miert, C, Woolfall, K and McNamara, PS




LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Rosala-Hallas, A, Jones, AP, Bedson, E, Compton, V, Fernandes, RM, Lacy, 
D, Lyttle, MD, Peak, M, Thorburn, K, van Miert, C, Woolfall, K and McNamara, 
PS (2020) National survey of feasibility of NIV trials for management of 
children with bronchiolitis. BMJ Paediatrics, 4 (1). ISSN 2399-9772 
LJMU Research Online
1Rosala- Hallas A, et al. BMJ Paediatrics Open 2020;4:e000780. doi:10.1136/bmjpo-2020-000780
Open access 
National survey of feasibility of NIV 
trials for management of children 
with bronchiolitis
Anna Rosala- Hallas   ,1 Ashley P Jones   ,1 Emma Bedson,1 Vanessa Compton,2 
Ricardo M Fernandes,3,4 David Lacy,5 Mark D Lyttle,6,7 Matthew Peak,8 
Kent Thorburn,2 Clare van Miert,2,9 Kerry Woolfall,10 Paul S McNamara11 
To cite: Rosala- Hallas A, 
Jones AP, Bedson E, et al. 
National survey of feasibility 
of NIV trials for management 
of children with bronchiolitis. 
BMJ Paediatrics Open 
2020;4:e000780. doi:10.1136/
bmjpo-2020-000780
Received 26 June 2020
Revised 7 August 2020
Accepted 25 August 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Paul S McNamara;  
mcnamp@ liverpool. ac. uk
Original research
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Background Bronchiolitis is a major cause of admission 
to hospital in children. Non- invasive ventilation (NIV) 
support with continuous positive airway pressure (CPAP) or 
high- flow nasal cannula (HFNC) oxygen is routinely used 
for infants in the UK with bronchiolitis.
Objective To establish UK paediatric practice regarding 
management of bronchiolitis, and to explore issues 
pertinent to the design of a potential future randomised 
controlled trial of NIV.
Design Screening logs were completed in hospitals in 
England capturing information on paediatric bronchiolitis 
admissions. An online national survey of clinical practice 
was disseminated to healthcare professionals (HCPs) 
across the UK to ascertain current management strategies.
Results Screening logs captured data on 393 infants 
from 8 hospitals. Reasons for admission were most 
commonly respiratory distress and/or poor fluid intake. 
Oxygen was administered for 54% of admissions. 
Respiratory (CPAP and HFNC) and non- respiratory support 
administered varied considerably. The national survey 
was completed by 111 HCPs from 76 hospitals. Data 
were obtained on criteria used to commence and wean 
NIV, responsibilities for altering NIV settings, minimum 
training requirements for staff managing a child on NIV, 
and numbers of trained staff. Most centres were interested 
in and capable of running a trial of NIV, even out of normal 
office hours.
Conclusions Respiratory and non- respiratory 
management of bronchiolitis in UK centres varies widely. 
A trial of HFNC oxygen therapy in this group of patients is 
feasible and HCPs would be willing to randomise patients 
into such a trial. Future work should focus on defining trial 
eligibility criteria.
INTRODUCTION
Bronchiolitis is a major cause of admission 
to hospital in children.1 2 Between 2004 and 
2012, 8172 children under the age of 1 year 
were admitted to a paediatric intensive care 
unit (PICU) for bronchiolitis in England.3 
From 2004 to 2011, the overall average PICU 
admission rate increased by 1.8% each year.3
Bronchiolitis management is centred 
on oxygen therapy for hypoxia, respira-
tory support and good hydration. Early use 
of non- invasive ventilation (NIV), such as 
continuous positive airway pressure (CPAP) 
or heated humidified high- flow nasal (HFNC) 
oxygen (O
2
), may have an impact on outcome 
by avoiding disease progression.4 There 
has been an increase in the use of HFNC in 
routine clinical practice for moderate- to- 
severe bronchiolitis; however, until recently, 
there has been little evidence to guide prac-
tice, and there have been no studies using NHS 
patients from the UK.5 6 Recently, a number 
of reports have raised concerns regarding its 
cost effectiveness in bronchiolitis.7
The objectives of this study were to assess 
current UK practice regarding bronchiol-
itis management in terms of the type of NIV 
methods used and the criteria for commencing 
and weaning NIV. We also wished to explore 
issues pertinent to the design of a potential 
future randomised controlled trial (RCT) 
of NIV. This study formed part of a larger 
research project (Non- Invasive Ventilation 
What is known about the subject?
 ► Bronchiolitis is one of the the most common causes 
of hospitalisation in infancy.
 ► Non- invasive ventilation and specifically high- flow 
nasal cannula oxygen therapy is increasingly used 
for children with bronchiolitis based on limited ev-
idence in the UK.
 ► There is widespread support among paediatricians 
in the UK for a trial of non- invasive ventilation to 
guide UK practice.
What this study adds?
 ► Respiratory and non- respiratory management of 
bronchiolitis in UK centres varies widely.
 ► A trial of high- flow nasal cannula oxygen therapy is 
feasible and healthcare professionals would be will-
ing to randomise patients into such a trial.
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for the Management of Children with Bronchiolitis: a 
feasibility study (NOVEMBR)).8
METHODS
A point- prevalence study, using paper screening logs of 
paediatric hospital admissions with bronchiolitis, was 
prospectively completed, by research nurses from district 
general hospitals and paediatric tertiary centres hospitals 
across England. The logs gave guidelines for completion 
and captured: patient age, referral route, demographic 
and clinical risk factors, reasons for admission, treatment 
interventions during admission, method of O
2
 delivery 
and amount of O
2
 (if any), and length of hospital stay. In 
total, 14 hospitals were approached for participation of 
which eight responded (five district general hospitals and 
three paediatric hospitals; see online supplemental list 1 
for a list of the hospitals). The logs were circulated in two 
waves: the first wave included five hospitals and ran from 
12 December 2016 to 12 January 2017; the second wave 
included three different hospitals from 11 December 
2017 to 13 January 2018. The same log was used for 
all hospitals; repeat sampling was not used. Data on all 
patients admitted with a diagnosis of bronchiolitis during 
these time periods to these hospitals were captured.
In addition, an online national survey (online supple-
mental material) was developed by the study manage-
ment group to explore current practices of HCPs when 
managing bronchiolitis. The survey was piloted among 
clinical members of the Study Management Group, which 
comprised PICU, respiratory and general paediatricians, 
paediatric nurses and research nurses. Amendments 
made from the piloting process were improvements to 
the clarity and understanding of the survey by changes 
to some of the language. The survey was disseminated 
to lead paediatricians at all paediatric centres in the UK 
through the National Institute for Health Research Clin-
ical Research Network (CRN) Coordinating Centre to 
Specialty Cluster Office for Children and Local CRNs, 
and through the General and Adolescent Paediatric 
Research Collaborative UK and Ireland. The lead paedi-
atricians were asked to complete the survey themselves 
or to pass it on to whoever they considered most appro-
priate. It was conducted online between 29 September 
2017 and 31 January 2018. Respondents were asked to 
report their job title and give information about their 
hospital including: the number of estimated paediatric 
bronchiolitis admissions, type of NIV interventions used 
and who administers them, criteria for initiating and 
weaning CPAP and HFNC, availability of local bronchiol-
itis care pathways and lastly, questions to determine the 
acceptability to HCPs of running a clinical trial. Comple-
tion of the survey was deemed consent to participate.
Data from both the screening logs and the online 
national survey were summarised using descriptive statis-
tics. Where questions were missed or responses ‘Not 
known’, percentages were derived using denominators 
for those who gave an answer only.
Advice from the HRA was sought and it was confirmed 
that ethical approval was not required for the online 
survey. Approval was not required for the screening exer-
cise as only anonymous data were collected.
Patient and Public Involvement (PPI) was not included 
forthis component of the NOVEMBR study since the aim 
was to ascertain currentpractice amongst HCPs.
RESULTS
Screening logs
Table 1 gives a summary of the screening data. Three 
hundred and ninety- three patients were screened at eight 
hospitals across England (online supplemental list 1). Data 
by hospital are presented in online supplemental table 1. 
The greatest proportion (139/357, 39%) were admitted 
in the afternoon and early evening (14:00–20:00). Median 
age at admission was 14 weeks (IQR: 8–29) and median 
length of hospital stay was 2 days (IQR: 1–3). Most refer-
rals were via emergency departments (246/391, 63%) or 
from general practitioners (99/391, 25%). It was possible 
for multiple reasons for admission to be selected for each 
patient; among the most frequent, over half (203/392, 
52%) reported difficulty with breast feeding/inadequate 
oral fluid intake, 36% (142/392) other respiratory prob-
lems, including cough and increased work of breathing, 
31% (121/392) severe respiratory distress and 27% 
(106/392) of children looked seriously unwell to a HCP. 
Commonly reported risk factors for hospital admission 
included age less than 3 months (165/357, 46%) and/
or prematurity (89/357, 25%); 34% (120/357) reported 
no risk factors. Non- respiratory interventions included: 
nasogastric fluids (157/354, 44%), antibiotics (87/354, 
25%), nebulised treatments (52/354, 15%) and intrave-
nous fluids (37/354, 10%); 38% (134/354) reported no 
treatment intervention. There was considerable variation 
across hospitals: nasogastric fluids use ranged from 17% 
to 77% of infants, antibiotics from 9% to 67%, nebu-
lisers from 7% to 55% and intravenous fluids from 1% 
to 37% (figure 1). Oxygen was delivered to 191 (54%) 
patients. Multiple methods for O
2
 delivery could be 
selected; methods reported were low- flow nasal cannula 
(103/191, 54%), rebreathe mask (42/191, 22%), head 
box with humidified O
2
 (25/191, 13%), HFNC (52/191, 
27%), CPAP (18/191, 9%) and intubation and ventila-
tion (21/191, 11%).
National online survey of current practice
The survey was accessed by 123 individuals. Twelve (9%) 
completed demographic details only and were excluded 
from the summaries; the remaining 111 (91%) responders 
were from 76 hospitals (online supplemental list 2). The 
majority (83/111, 75%) of respondents were from district 
general hospitals; 25% (28/111) were from paediatric 
tertiary centres. According to the Royal College of Paedi-
atrics and Child Health workforce document published 
in 2019, there are 189 paediatric centres with inpatient 
facilities in the UK of which 35 are considered specialist 
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(tertiary) centres.9 Respondents were either consultants 
(92/109, 84%) or nurses (12/109, 11%, table 2).
Almost half (47%, 38/81) of respondents stated that 
the estimated annual number of paediatric bronchiolitis 
admissions to their hospital with a length of stay of at least 
1 day, was between 101 and 200, and 30% (24/81) esti-
mated between 51 and 100. The majority (71/84, 85%) 
of respondents stated local bronchiolitis care pathways 
and/or guidance were available to them; 86% (75/87) 





Six respondents (6/88, 7%), from separate hospitals, 




Table 1 Screening data
N (%)
Patient age (weeks)
  N 378
  Mean (SD) 20.0 (15.9)
  Median (IQR) 14.2 (7.5–29.1)
  Min, Max 1.3–82.4
  Missing 15
Length of stay in hospital (days)
  N 390
  Mean (SD) 2.7 (3.0)
  Median (IQR) 2 (1.3)
  Min, max 0–24
  Missing 3
Time of presentation
  N 357
  02:00–08:00 36 (10%)
  08:00–14:00 81 (23%)
  14:00–20:00 139 (39%)
  20:00–02:00 101 (28%)
  Missing 36
Referral route
  N 391
  Accident and emergency 246 (63%)
  District general hospital 16 (4%)
  General practitioner 99 (25%)
  Open access 17 (4%)
  Other hospital 10 (3%)
  Readmission 1 (0.3%)
  Walk- in 2 (0.5%)
  Not known 2
Risk factors*
  N 357
  Baby born prematurely 89 (25%)
  Congenital heart defect 7 (2%)
  Neuromuscular disease 1 (<1%)
  Immunodeficiency disorders 2 (1%)
  Chronic lung disease 8 (2%)
  Young age (≤3 months) 165 (46%)
  Other 24 (7%)
  No risk factors 120 (34%)
  Not known 1
  Missing 35
Reason for admission*
  N 392
  Apnoea (reported or observed) 21 (5%)
  Child looks seriously unwell to a HCP 106 (27%)
Continued
N (%)
  Severe respiratory distress 121 (31%)
  Central cyanosis 3 (1%)
  Persistent O
2
 saturation <92% when 
breathing air
30 (8%)
  Difficulty with breast feeding/
inadequate oral fluid intake
203 (52%)
  Social circumstances 2 (1%)
  Other respiratory 142 (36%)
  Other 50 (13%)




  N 191
  Nasal Cannula 103 (54%)
  Headbox with humidified O
2
25 (13%)
  Heated humidified high- flow nasal O
2
52 (27%)
  Rebreathe mask 42 (22%)
  CPAP 18 (9%)
  Intubation and ventilation 21 (11%)
  Other 13 (7%)
  No O
2
 used 162
  Not known 3
  Missing 37
*Multiple responses could be selected.
CPAP, continuous positive airway pressure; HCP, healthcare 
professional.
Table 1 Continued
Figure 1 Screening responses—treatment interventions 
across hospitals.
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CPAP/HFNC
More respondents reported being able to deliver O
2
 
on paediatric wards by HFNC (73/86, 85%) than CPAP 
(49/86, 57%); 55% reported the ability to deliver O
2
 
using both treatment modalities. On High Dependency 
Units (HDU), the ability to deliver O
2
 using either was 
similar (HFNC, 70/73, 96%; CPAP, 64/73, 88%).
The modal estimate of infants with bronchiolitis that 
did not require O
2
 on admission reported by respon-
dents was 11%–20%, whereas the estimate of infants that 
did require O
2
 was 61%–70%. Although the modal esti-
mate of infants treated with CPAP or HFNC was similar 
(0%–10%), the variation was more marked for HFNC, 
with some respondents estimating that up to 80% of 
patients requiring NIV in their centres would be treated 
with HFNC, compared with a maximum of 40% estimated 
to be treated with CPAP (online supplemental table 5).
Apnoea, type 2 respiratory failure, exhaustion and 
the child not improving on alternate therapies (mostly 
HFNC) were more commonly cited as criteria to 
start CPAP compared with HFNC (figure 2, online 
Table 2 Survey participant/hospital demographics





  N 109
  Consultant 92 (84%)
  Nurse 12 (11%)
  Other 5 (5%)
  Missing 2
Number of children with bronchiolitis admitted to hospital 
(with ≥1 day length of stay) per year
  N 81
  <50 5 (6%)
  51–100 24 (30%)
  101–200 38 (47%)
  201–300 9 (11%)
  301–400 2 (2%)
  >401 3 (4%)
  Not known 28
  Missing 2
Local bronchiolitis care pathways and/or guidance available
  N 84
  Yes 71 (85%)
  No 13 (15%)
  Not known 6
  Missing 21
Criteria for starting O
2
  N 87
  SpO
2
 <92% 75 (86%)
  Other 12 (14%)
  Not known 2
  Missing 22
Do you send otherwise well children with bronchiolitis who 
are improving, home on O
2
?
  N 88
  Yes 6 (7%)
  No 82 (93%)
  Not known 3
  Missing 20
Methods to deliver O
2
: therapy on the general medical 
practice ward*
  N 86
  Nasal cannula 84 (98%)
  Heated humidified high- flow nasal O
2
73 (85%)
  Rebreathe mask 50 (58%)
  Non- invasive CPAP 49 (57%)








  Missing 25
Methods to deliver O
2
: therapy on the High 
Dependency Unit*
  N 73
  Heated humidified high- flow nasal O
2
70 (96%)
  Non- invasive CPAP 64 (88%)
  Nasal cannula 56 (77%)
  Rebreathe mask 39 (53%)
  Headbox with humidified O
2
19 (26%)
  Missing 38
*Multiple responses could be select.
CPAP, continuous positive airway pressure.
Table 2 Continued
Figure 2 Survey responses—criteria for initiating 
continuous positive airway pressure (CPAP) compared to 
high- flow nasal cannula (HFNC).
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supplemental table 3); HFNC was started for increased 
work of breathing more often than CPAP. Correspond-
ingly, resolved apnoea, and improved C02/respiratory 
acidosis were more commonly cited as criteria for weaning 
CPAP compared with HFNC. Responsibilities for altering 
CPAP/HFNC settings lay predominantly with the nursing 
staff, who were responsible in 40% (23/57) of cases on 
CPAP compared with 77% (46/60) of cases on HFNC. 
Minimum training requirements for staff to manage a 
child on CPAP/HFNC were similar for both methods and 
included: annual attendance of in- house training pack-
ages with and without clinical competency assessments, 
attendance to ad hoc training sessions run by equipment 
manufacturers and high dependency courses.
Acceptability of a trial
Most respondents (34/41, 83%) reported that it would 
be possible to run a clinical trial evaluating NIV treatment 
approaches in bronchiolitis even out- of- hours at their 
hospitals (online supplemental table 4). Forty respond-
ents suggested at least one barrier to undertaking such 
a trial. Barriers included: current medical/nursing staff 
workload (15/40, 38%), availability of equipment (7/40, 
18%), lack of research nurse support (4/40, 10%) and 
lack of adequately trained staff to undertake a trial (3/40, 
8%). Correspondingly, 47 respondents suggested at least 
one enabler to undertaking a trial: having adequate 
medical, nursing and research nurse support (24/47, 
51%), good training and education about any trial (8/47, 
17%) and importantly, having access to extra equipment 
(8/47, 17%). Sixty per cent (47/78) estimated that 1–5 
HDU beds would be available in winter.
Respondents at 72% of sites reported always having 
one or more GCP trained doctor on every shift. Similarly, 
respondents at 45% of sites reported that their site had 
one or more GCP trained nurse on every shift.
DISCUSSION
In this prospective observational study of bronchiolitis 
admissions, large numbers of children (particularly young 
infants approximately 3 months of age) were hospital-
ised with this condition but generally for only a few days. 
Many (46%) did not require oxygen during their admis-
sion, but in those who did, the method by which it was 
administered varied widely; this was particularly so for 
those requiring NIV. Despite publication of The National 
Institute for Health and Care Excellence (NICE) guide-
lines on bronchiolitis in 2015,3 there remains consider-
able variation in other aspects of management.
This study provided the opportunity to compare survey 
responses from a large number of UK paediatric HCPs 
with screening log data on actual bronchiolitis admis-
sions to secondary and tertiary centres. Survey responses 
overestimated the proportion of children requiring O
2
 
on admission compared with screening log data, and 
although modal estimates of CPAP usage were broadly 
in line with actual usage, estimates of HFNC usage 
underestimated actual usage. In interpreting these 
results, it should be acknowledged that the screening log 
data were based on admissions to only eight paediatric 
centres, and that there was a wide range of estimates of 
percentages of children treated with O
2
 and with NIV 
(particularly HFNC). It may also be the case that the 
screening results differ between district general hospitals 
and paediatric tertiary centres; however, our sample size 
did not permit such a comparison.
We compared reasons for starting and weaning NIV. 
Apnoea, type 2 respiratory failure, exhaustion and the 
child not improving on alternate therapies (mostly 
HFNC) were more commonly cited as criteria to start 
CPAP. Correspondingly, resolved apnoea, and improved 
C0
2
/respiratory acidosis were more commonly cited as 
weaning criteria for CPAP than HFNC. The overall consis-
tency of approach to starting and weaning NIV suggests 
the need for a consensus- based clinically pragmatic 
protocol for any future trial, and that agreeing criteria 
and a protocol to initiate and wean NIV across sites in 
a future trial is feasible. Furthermore, such criteria have 
already been adopted for a UK- based pragmatic trial in 
critically ill children on both stepping up and stepping 
down non- invasive respiratory support.10
Based on our findings, we would question whether it 
is currently feasible for a HFNC versus CPAP trial to be 
undertaken outside of PICUs and high- dependency units 
in the UK. This is primarily for reasons of capacity/capa-
bility, with many centres unable to support the use of CPAP 
on general paediatric wards and also given the recent 
funding and start of the FIRST- ABC (First- line support 
for Assistance in Breathing in Children) trial which is 
examining the non- inferiority of HFNC compared with 
CPAP.10 However, a trial to assess the clinical effectiveness 
of HFNC versus standard oxygen therapy (‘standard’ 
agreed a priori) is feasible and one which many general 
paediatricians would likely support. A key issue for any 
such trial would be eligibility criteria. NOVEMBR and 
recently published RCTs of NIV for bronchiolitis suggest 
that eligibility cannot be based solely on the need for 
oxygen.5 6 We have shown here that although over half 
children hospitalised with bronchiolitis are hypoxic on 
admission, most do not require O
2
 for long (under 24 
hours), do not deteriorate that frequently, and do not 
have prolonged inpatient admissions. Even for those 
hypoxic children at high risk of severe bronchiolitis (ie, 
those less than 3 months of age or born prematurely), 
the median (IQR) length of stay in hospital was only 2 
(1–3) days. Key eligibility criteria for any future trial will 
likely have to include both need for O
2
 and increased 
work of breathing, and take into account risk factors such 
as young age/prematurity. It is these infants for whom 
HFNC likely has the biggest potential to demonstrate 
clinical and cost effectiveness. A retrospective cohort 
study published in 2018 identified predictors of escalated 
care in bronchiolitis and used these to derive a risk score 
to outline higher risk patients; validation of such a score 
would be beneficial.11
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The screening logs highlighted a large variation 
in the frequency with which various non- respiratory 
interventions were used in children with bronchiolitis. 
Variation on this scale has previously been reported 
between countries, but not to our knowledge within 
the UK.12 When designing potentially large multicentre 
trials of NIV for children with bronchiolitis, an appreci-
ation of this sort of variation in practice may be needed 
when planning patient recruitment per site and trial 
acceptability.
There were two limitations of note, the first being 
that in the survey multiple responses from the same 
hospital could have inflated the proportions for certain 
responses. To check the validity of our results, we looked 
at the results with each hospital included only once for 
each response level (online supplemental tables 2-4) 
and found that the proportions were similar. The second 
limitation was that participants from the same hospital 
occasionally reported different answers, which is likely 
due to different perspectives depending on the job roles 
of the respondents; however, sample sizes prevented us 
from exploring differences between HCP subgroups (ie, 
nurses from general paediatric wards and those from 
HDU).
We have established that there is a wide variety of prac-
tice across the UK in the respiratory and non- respiratory 
treatments given to infants with bronchiolitis. Our results 
also suggest that a trial of NIV is feasible and that HCPs 
would be willing to randomise patients into an NIV trial. 
Future work should now focus on defining the eligibility 
criteria for such a trial.
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